didimethylsulfoxide-dichloroplatinum(ii) and Nasopharyngeal-Neoplasms

Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Epirubicin; Female; Fluorouracil; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Organoplatinum Compounds

Combination therapy with cisplatin (CDDP) and UFT, a drug prepared with 1-(tetrahydro-2-furanyl)-5-fluorouracil and uracil at a mixing molar ratio of 1:4, was examined in nude mice bearing transplantable human nasopharyngeal hybrid cell (A2L/AH). The tumor growth of A2L/AH was inhibited in the group administered UFT 20 mg/kg, but was not in 10 mg/kg group in comparison with the control group. An inhibition rate (IR) of the tumor growth at 20 mg/kg and 10 mg/kg doses was 80.2 and 21.3%, respectively. The group received CDDP (5 mg/kg, q7d x 3, 2 mg/kg, q7d x 3, and 1 mg/kg, qd x 6) by intraperitoneal injection, resulted in 75.2, 37.4, and 23.1% inhibitions, respectively. While, the response rate in the group treated with CDDP (1 mg/kg, qd x 6) and UFT (10 mg/kg) showed a synergistic effects (IR, 66.3%) which was higher than in the group administered CDDP (2 mg/kg, q7d x 3) and UFT (10 mg/kg) (IR, 58.3%).

Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Synergism; Injections, Intraperitoneal; Mice; Nasopharyngeal Neoplasms; Neoplasm Transplantation; Organoplatinum Compounds; Tegafur; Uracil